| University of Maryland, Baltimore Patent applications |
| Patent application number | Title | Published |
|---|
| 20120109124 | ELECTROSURGICAL ELEMENT AND UTERINE MANIPULATOR FOR TOTAL LAPAROSCOPIC HYSTERECTOMY - A vaginal cervical retractor used to maneuver and visualize the uterus during various medical examinations and procedures would include an inner tube provided with a movable assembly of plastic cups (cervical cup and vaginal cup) designed to be inserted into the uterine cavity and a retractable electrosurgical needle. A cervical cup is molded to a hollow outer shaft to form the movable cup assembly. This hollow shaft is provided through which the inner tube can be inserted. By utilizing a vaginal cervical retractor elevator provided with an inner rigid tubing, freely sliding vaginal cup and cervical cup designed to move on the inner tubing, attached to a hollow, plastic outer shaft into which the inner tubing can be inserted, and a retractable, flexible, electrosurgical needle, the colpotomy procedure can be performed with the improved uterine manipulator. | 05-03-2012 |
| 20120107329 | EGFR and PAR2 Regulation of Intestinal Permeability - The present invention provides methods for diagnosing and treating an immune-mediated disease, e.g., an autoimmune disease, an allergy or an inflammatory disease. Diagnosis is made by detecting a heterozygous or homozygous genotype of haptoglobin 2 or by detecting and quantifying pre-haptoglobin 2 mRNA or protein. After diagnosis, the disease may be treated by decreasing cell permeability leading to increased transepithelial electrical resistance, for example, by administering an antibody directed against single chain zonulin thereby inhibiting epidermal growth factor receptor and inhibiting proteinase-activated receptor 2 (PAR | 05-03-2012 |
| 20120078206 | SNAP-ON TWO-PIECE EMERGENCE PROFILE HEALING ABUTMENT - The present invention relates to an apparatus for the removal and containment of human waste products from the effected area of incontinent patients. The apparatus and process encapsulates the areas of the body where urine and fecal matter are excreted. In particular, the present invention is directed to an apparatus for the containment and removal of human waste products, comprising: a receptacle; a vacuum connection to apply force for attaching the receptacle to the patient; and a vacuum dispersion membrane to provide mechanical support to the skin so as to minimize tensile force applied to the skin. | 03-29-2012 |
| 20120076861 | MATERIALS AND METHODS FOR THE TREATMENT OF CELIAC DISEASE - The present invention provides materials and methods for the treatment of celiac disease. In addition, the present invention provides materials and methods of monitoring the treatment of a subject having celiac disease. | 03-29-2012 |
| 20120076722 | METHODS FOR TREATING CANCERS AND DISEASES ASSOCIATED WITH 4-1BB (CD137) EXPRESSION - The present invention relates to the role of 4-1BB (CD137) ligand and anti-4-1BB (CD137) antibody in the treatment of cancers and diseases associated with 4-1BB (CD137) expression. More particularly, the present invention relates to the use of (i) 4-1BB (CD137) ligand for inducing proliferation and activation and promoting survival of B lymphocytes and (2) anti-4-1BB (anti-CD137) antibody for inhibiting proliferation and activation and inducing death of B lymphocytes. | 03-29-2012 |
| 20120064105 | Engineered Type IV Pilin of Clostridium difficile - The present invention relates to engineered | 03-15-2012 |
| 20120064074 | ANTIGEN BINDING DOMAINS - A process for the production of an antigen specific antigen binding domain using a transformed host containing an expressible DNA sequence encoding the antigen specific antigen binding domain, wherein the antigen specific antigen binding domain is derived from a variable region of the immunoglobulin isotype NAR found in fish. | 03-15-2012 |
| 20120046363 | DOCOSAHEXAENOIC ACID FOR THE TREATMENT OF HEART FAILURE - There is currently no completely effective treatment for heart failure. Considering the need for, and current void in the medical field for, a treatment for heart failure, the invention is drawn to treating heart failure. In particular aspects, the invention is drawn to the discovery that certain polyunsaturated fatty acids (PUFAs) and doses thereof are useful for treating heart failure. In other particular aspects, the invention is drawn to the discovery that certain PUFAs and doses thereof are useful for preserving mitochondrial function in a heart failure subject. | 02-23-2012 |
| 20120046324 | SMALL MOLECULE INHIBITORS OF KYNURENINE-3-MONOOXYGENASE - The present invention relates to compounds of Formula I below and their tautomers or pharmaceutically acceptable salts, compositions and methods of uses thereof. | 02-23-2012 |
| 20120034620 | COMPOSITIONS AND METHODS FOR ADHESION OF INTACT CELLS TO AN APPARATUS - Bio-adhesive compositions that include an extra-cellular matrix protein, bovine serum albumin conjugated with a fluorophore, and an aggregate are provided. The bio-adhesive composition may also include at least one component selected from the group consisting of collagen type IV, laminin, and chitosan. Also provided are methods of making the present compositions, that include taking a desired amount of extracellular matrix gel to liquid form of extracellular matrix; adding a desired amount of bovine serum albumin conjugated with a fluorophore; adding a desired amount of aggregate; and mixing. Further provided are methods for attaching cells to an apparatus using the present bio-adhesive compositions, and methods of attaching the present bio-adhesive compositions to an apparatus. Also provided are kits that include the present composition, components thereof or apparatuses, having the present composition attached thereto. | 02-09-2012 |
| 20120029173 | ATTENUATED SALMONELLA ENTERICA SEROVAR PARATYPHI A AND USES THEREOF - The present invention is drawn to a live, attenuated | 02-02-2012 |
| 20120022052 | SMALL MOLECULE INHIBITORS OF KYNURENINE-3-MONOOXYGENASE - The present invention relates to compounds of formula Ia or Ib below and their tautomers and/or pharmaceutically acceptable salts and compositions and methods of uses thereof. | 01-26-2012 |
| 20120010531 | Small-Animal Unit for Muscle Injury, Muscle Testing and Muscle Training in Vivo - The invention provides a system for measuring contractile torque of skeletal muscles, performing muscle training programs, and inducing contraction-induced injury. The system is versatile and precise to measure contractile torque, train muscles, and perform contraction-induced injury protocols on living rodents. The system also allows for repeated studies of the same animal over time, thus resembling longitudinal human studies, minimizing the effect of animal-to-animal variability, and reducing the total number of animals that need to be studied. | 01-12-2012 |
| 20120009242 | BLOOD COAGULATION INDUCING POLYMER HYDROGEL - The present application is drawn to a synthetic, polymer hydrogel-based material, which is able to actively induce the body's natural hemostatic coagulation process in blood or acellular plasma. The present invention provides the development of a primary amine containing polymer hydrogel capable of inducing blood coagulation and delivering therapeutics for hemostatic or wound care applications, and a method of forming such a primary amine containing polymer hydrogel capable of inducing the blood coagulation process. The primary amine containing polymer hydrogel is able to achieve the same end result as biological-based hemostatics, without the innate risk of disease transmission or immunological response, and at a fraction of the price. Furthermore, due to its inherent hydrogel-based design the material has the capability of arresting blood loss while simultaneously delivering therapeutics in a controlled manner, potentially revolutionizing the way in which wounds are treated. | 01-12-2012 |
| 20120004518 | TECHNIQUES FOR COMPENSATING MOVEMENT OF A TREATMENT TARGET IN A PATIENT - One embodiment includes a method of predicting a position of a target site inside a body using surrogates is provided. The method includes transforming surrogate measurements and target positions into different representations by applying an operator, establishing a special relationship between the transformed surrogate measurements and the transformed target positions, and continuously predicting the target position from the transformed surrogate measurements and the established special relationship. | 01-05-2012 |
| 20110311118 | Techniques for 3-D Elastic Spatial Registration of Multiple Modes of Measuring a Body - Techniques for registration of multiple measurement modes of a body include receiving first and second data from different modes. Each includes measured values with coordinate values. For two mechanically aligned modes, any non-rigid registration is performed. For some modes, the non-rigid registration includes a coarse transformation and multiple fine scale transformations. The coarse transformation maximizes a coarse similarity measure. The second data is sub-divided into contiguous sub-regions. Fine transformations are determined between the sub-regions and corresponding portions of the first data to maximize a fine similarity measure. Sub-dividing and determining fine transformations repeats until stop conditions are satisfied. Transformations between the last-divided sub-regions are interpolated. Any of the fine similarity measure, a search region, interpolation method, sub-division location, and the use of rigid or non-rigid fine transformations are adaptive to properties of the first or second data so that the registration is automatic without human intervention. | 12-22-2011 |
| 20110293161 | Techniques for Tomographic Image by Background Subtraction - Techniques for background subtraction in computed tomography include determining voxels in a slice of interest in a three dimensional computed tomography scan of the interior of a body based on a first set of measurements of radiation transmitted through the body. Based on the first set of measurements, a first background image for radiation transmitted through the body in a first direction is determined without the effects of the voxels in the slice of interest. A current image is determined based on a different current measurement of radiation transmitted through the body in the first direction. A first difference is determined between the current image and the first background image. The result is a high contrast image in the slice of interest even from a single current projection image. | 12-01-2011 |
| 20110274714 | Broad Spectrum Vaccine Against Non-Typhoidal Salmonella - The present invention is drawn to attenuated | 11-10-2011 |
| 20110223615 | Rapid Expression Cloning of Human Monoclonal Antibodies from Memory B Cells - The present application provides methods for producing human monoclonal antibodies without using hybridoma technology, antibodies produced used the described methods, and methods for using the antibodies to treat or prevent disease conditions (e.g., infection by pathogens such as the Human Immunodeficiency Virus). | 09-15-2011 |
| 20110218239 | Use of 5,6-Dimethylxanthenone-4-Acetic Acid as an Antiviral Agent - The invention relates to the areas of therapeutics, pharmaceuticals, drug discovery, and immunotherapy. More specifically, the present invention relates to methods of stimulating the immune system through the administration of flavone acetic acid [FAA] analogues, and in particular, the flavone acetic acid analogue, 5,6-dimethylxanthenone-4-acetic acid (DMXAA) so as to comprise an antimicrobial therapeutic agent for the treatment of viral infections of DNA and RNA viruses in humans and non-human animals. The invention is especially suitable for use in a process of treating and preventing infection by, for example, rhinoviruses, enteroviruses, and influenza viruses. | 09-08-2011 |
| 20110217241 | CONJUGATES OF 19F MR IMAGING TRACERS FOR USE IN MULTI-CHROMIC MRI IMAGING - Compositions for producing multi-chromic (“color”) magnetic resonance images (MRI). The compositions for use as MRI imaging agents include a magnetic resonance imaging tracer having a signal emitter, such as a | 09-08-2011 |
| 20110193882 | TECHNIQUES FOR 3-D ELASTIC SPATIAL REGISTRATION OF MULTIPLE MODES OF MEASURING A BODY - Techniques for registration of multiple measurement modes of a body include receiving first and second data from different modes. Each includes measured values with coordinate values. For two mechanically aligned modes, any non-rigid registration is performed. For some modes, the non-rigid registration includes a coarse transformation and multiple fine scale transformations. The coarse transformation maximizes a coarse similarity measure. The second data is sub-divided into contiguous sub-regions. Fine transformations are determined between the sub-regions and corresponding portions of the first data to maximize a fine similarity measure. Sub-dividing and determining fine transformations repeats until stop conditions are satisfied. Transformations between the last-divided sub-regions are interpolated. Any of the fine similarity measure, a search region, interpolation method, subdivision location, and the use of rigid or non-rigid fine transformations are adaptive to properties of the first or second data so that the registration is automatic without human intervention. | 08-11-2011 |
| 20110184225 | STEP TRAINER FOR ENHANCED PERFORMANCE USING RHYTHMIC CUES - A person's step length and rate may be measured, for example, through sensors that collect spatial and temporal gait parameter data. The measurements are then used to determine the rate of a rhythmic auditory cue to improve the person's gait. For example, a system links sensors to detect step rate and length to an audio cue provided to headphones, while providing the appropriate algorithms to accomplish real time adjustments to the audio cues as needed to better help change the person's step length vs. step rate ratio in a desired direction depending on therapeutic or performance goals. | 07-28-2011 |
| 20110183923 | PEPTIDE ANTAGONISTS OF ZONULIN AND METHODS FOR USE OF THE SAME - Peptide antagonists of zonulin are disclosed, as well as methods for the use of the same. The peptide antagonists bind to the zonula occludens receptor, yet do not physiologically modulate the opening of mammalian tight junctions. | 07-28-2011 |
| 20110179361 | PREDETERMINED PRESENTATION OF PATIENT DATA AT BEDSID - Techniques for presenting patient data at the patient's bedside include receiving predetermined presentation style data that indicates a subset of fewer than all parameters available from an electronic medical records (EMR) system and a first arrangement on a display device of related parameters in the subset. Without human intervention, the most recent values from the EMR system are received. The most recent values are associated in the EMR system with the particular patient for corresponding parameters of the subset. A first most recent value is presented according to the first arrangement at the particular bedside display device without human intervention. In some embodiments, the most recent values are also received or presented in response to a single stroke from a human user at an input for the particular display device. | 07-21-2011 |
| 20110177111 | PROTECTIVE VACCINE AGAINST STAPHYLOCOCCUS AUREUS BIOFILMS COMPRISING CELL WALL-ASSOCIATED IMMUNOGENS - Vaccine formulations effective against | 07-21-2011 |
| 20110171123 | In Vivo Biofilm Infection Diagnosis and Treatment - The present invention relates to a method for in vivo detection of a biofilm infection residing in a mammal, the method comprising (i) administering to the mammal a diagnostic-effective amount of a biofilm-specific probe, wherein the probe comprises a bio film-targeting moiety and a paramagnetic nanoparticle core; and (ii) imaging the mammal to detect the presence of the biofilm infection by observing the mammal using a magnetic resonance diagnostic technique after the biofilm-specific probe has been provided sufficient time to selectively bind to the bio film infection that may be present in the mammal. The invention also relates to methods of treatment of a bio film infection, and compositions and kits useful in the detection and/or treatment of bio film infections. | 07-14-2011 |
| 20110144093 | METHOD OF TREATING ORGANOPHOSPHOROUS POISONING - A method for treating organophosphorous poisoning (OP) comprising administering to a mammal at risk for OP poisoning an OP poisoning-inhibiting amount of galantamine. | 06-16-2011 |
| 20110118219 | NOVEL PRODRUGS OF C-17-HETEROARYL STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS: SYNTHESIS, IN VITRO BIOLOGICAL ACTIVITIES, PHARMACOKINETICS AND ANTITUMOR ACTIVITY - Prodrugs of steroidal C-17 benzoazoles, pyrimidinoazoles(azabenzoazoles) and diazines. Methods of synthesis are also described, whereby a prodrug group is substituted for a functional group at A ring portion of the ABC ring structure of the steroid. Suitable prodrug groups include amino acid groups, succinate groups, phosphate groups, or sulfamate groups. The prodrugs of the disclosed compounds allow for improved oral bioavailability of the compounds that are inhibitors of human CYP17 enzyme as well as potent antagonists of both wild type and mutant androgen receptors (AR). The compounds and the corresponding prodrugs are useful for the treatment of conditions such as human prostate cancer, breast cancer, and prostate hyperplasia. | 05-19-2011 |
| 20110105445 | ANDROGEN RECEPTOR INACTIVATION CONTRIBUTES TO ANTITUMOR EFFICACY OF CYP17 INHIBITORS IN PROSTATE CANCER - Provided are methods of inhibiting CYP17 in a mammal, such as a human, that include administering an effective amount of at least one CYP17 inhibitor, such as VN/124-1, VN/125-1, VN/85-1, VN/87-1 and/or VN/108-1 to the mammal. Also provided are methods of down regulating androgen receptor (AR) protein expression and methods of antagonizing AR in a mammal that include administering to the mammal an effective amount of at least one active ingredient selected from VN/124-1, VN/125-1, VN/85-1, VN/87-1 and VN/108-1. Also provided are methods of treating prostate cancer and methods of suppressing or preventing prostate tumor growth by administering such compounds to a mammal. | 05-05-2011 |
| 20110098935 | TECHNIQUES FOR DETERMINING THE EFFECTS ON A SYSTEM OF A COMPONENT THAT HAS FOUR STATES - Techniques for determining effects on a biological system include determining rate constants for a particular time interval starting at an initial time. Each rate constant indicates a rate of transition from one of four states to a different one of the four states for a component of a biological system in presence of an external factor. A temporal change in a probability that the component is in a particular state after the initial time is determined without numerical iteration over multiple time steps. This includes determining three relaxation time constants that describe exponential changes based on the rate constants. The effect of the external factor on the biological system is determined based on the temporal change in the probability that the component is in the particular state. The probability at an arbitrary time is determined based on the rate constants and initial probabilities. | 04-28-2011 |
| 20110086059 | NON-HEMOLYTIC CLYA FOR EXCRETION OF PROTEINS - The disclosure below provides a protein export system utilizing non-hemolytic variants of HlyE family member proteins for efficiently producing recombinant protein from a host cell. In a preferred embodiment, the protein export system utilizes protein export machinery endogenous to the host bacterium into which the protein export system vector is introduced. | 04-14-2011 |
| 20110070252 | MAGE-A3/HPV 16 PEPTIDE VACCINES FOR HEAD AND NECK CANCER - The present invention relates to Trojan antigens, and immunogenic compositions comprising the Trojan antigens. The present invention also relates to methods of generating an immune response in a subject using the Trojan antigens or immunogenic compositions. The present invention further relates to methods of treating squamous cell carcinoma of the head and neck (SCCHN) using the Trojan antigens and immunogenic compositions of the present invention. | 03-24-2011 |
| 20110059974 | NOVEL RETINAMIDE RETINOIC ACID METABOLISM BLOCKING AGENTS - Retinoic acid metabolism blocking agents (RAMBAs). The RAMBAs may be used for treatment of cancer, including breast and prostate cancers. Methods for preparing novel retinamide RAMBAs. The methods include reacting RAMBAs with terminal polar carboxylic acid group with a variety of amines in the presence of suitable coupling reagents. The retinamide RAMBAs are potent inhibitors of the growth of prostate and breast cancer cells and may be useful for the treatment of these diseases in humans. | 03-10-2011 |
| 20110052033 | COMPOSITE IMAGES FOR MEDICAL PROCEDURES - Medical imaging often involves the collective use of information presented in multiple images of an individual, such as images generated through different imaging modalities (X-ray, CT, PET, etc.) The use of a composite of these images may involve image registration to adjust for the variable position and orientation discrepancies of the individual during imaging. However, registration may be complicated by soft tissue deformation between images, and implementations (particularly pure software implementations) of the mathematical models used in image registration may be computationally complex and may require up to several hours. Hardware architectures are presented that apply the mathematical techniques in an accelerated manner, thereby providing near-realtime image registration that may be of particular use for the short timeframe requirements of surgical environments. The composite image generated thereby may be used to target anatomic features of interest during various medical procedures, including surgical procedures. Moreover, such techniques may be applied to computationally difficult image processing techniques, such as the display of a composite image based at least in part on a PET image, which may otherwise be difficult to utilize in a time-sensitive manner such as a surgical setting. | 03-03-2011 |
| 20110045554 | HETEROLOGOUS EXPRESSION OF EXTREMOPHILE HEAT SHOCK PROTEINS AND CHAPERONES IN MICROORGANISMS TO INCREASE TOLERANCE TO TOXIC COMPOUNDS - The invention provides methods and compositions for increasing tolerance of microorganisms to toxic agents, such as solvents; and for increasing production of solvents from solvent-generating microorganisms. The methods comprise engineering a microorganism of interest to express a heterologous heat-shock protein/chaperone, e.g., Group II chaperonin or a prefoldin such as γ-prefoldin, where the heterologous protein is from an extremophile, such as an archaean. | 02-24-2011 |
| 20110021440 | APOPTOTIC PATHWAY TARGETING FOR THE DIAGNOSIS AND TREATMENT OF CANCER - The invention relates to methods of treating cancer. The invention further relates to a method of treating cancer by exploiting apoptotic pathways. The invention particularly relates to regulation of apoptotic pathways in cancerous cells, to metastasis of cancer cells, and to methods of preventing cancer metastasis. | 01-27-2011 |
| 20110020399 | Vaccines and Immunomodulatory Therapies for Tularemia - The present invention relates to attenuated strains of | 01-27-2011 |
| 20110004189 | SYSTEM AND METHOD FOR PROVIDING OPTIMAL CONCENTRATIONS FOR MEDICATION INFUSIONS - Techniques for medical infusions include determining a first infusion rate for administering a first medication to a patient. A fluid load is determined based at least in part on the first infusion rate. It is determined whether the fluid load exceeds a predetermined threshold based on a fluid maintenance rate. If it is determined that the fluid load exceeds the predetermined threshold, then an action is caused to inhibit administering the first medication to the patient at the first infusion rate. | 01-06-2011 |
| 20100291069 | METHODS OF TREATING A DIABETIC EMBRYOPATHY - Maternal diabetes can lead to a developmental malformation of an embryo. A developmental malformation caused by maternal diabetes is commonly referred to as a diabetic embryopathy. There is currently no effective treatment for reducing or inhibiting a diabetic embryopathy. To this end, the present invention is drawn to novel methods of treating a diabetic embryopathy. | 11-18-2010 |
| 20100285496 | Methods and Devices for the Detection of Biofilm - The present invention provides methods and kits for biofilm detection. | 11-11-2010 |
| 20100268154 | APPARATUS AND METHOD FOR AUTOMATING AN ENEMA WITH CONTROLLED DISTENSION - An apparatus and method are provided for use in administering a rectal contrast enema to a patient to prepare the patient for a medical procedure. A rectal catheter may be provided to facilitate administration of the enema preparation to the patient. The rectal catheter may include a retention balloon. A delivery mechanism may be provided to urge the enema preparation into the patient. A vacuum may be provided to remove waste from the patient. A gas insufflator may be provided to insufflate the patient's colon for a medical procedure such as a scan, and more specifically, a virtual colonoscopy. | 10-21-2010 |
| 20100262203 | DETERMINATION OF SITE OF ORIGIN FOR A NATURAL ELECTRICAL PULSE IN A LIVING BODY - Techniques include determining a first vector of temporal changes in electrical data measured at multiple electrical sensors positioned at corresponding locations on a surface of a living body due to a natural electrical pulse. A different vector of temporal changes in electrical data measured at the same electrical sensors is determined due to each stimulated signal of multiple stimulated signals within the living body. Stimulated position data is received, which indicates a different corresponding position within the living body where each of the stimulated signals originates. The site of origin of the natural electrical pulse is determined based on the first vector and the multiple different vectors and the stimulated position data. Among other applications, these techniques allow the rapid, automatic determination of the site of origin of ventricular tachycardia arrhythmia (VT). | 10-14-2010 |
| 20100239633 | IMMUNOGLOBULIN CONSTANT REGION FC RECEPTOR BINDING AGENTS - IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases. | 09-23-2010 |
| 20100204751 | Methods for Treating Central Pain Syndrome and Other Pain Related Pathologies - Central pain syndrome (CPS) is a debilitating condition that affects a large number of patients with a primary lesion or dysfunction in the central nervous system. Despite its discovery over a century ago, the pathophysiology underlying the development and maintenance of CPS is poorly understood. The present invention is drawn to novel methods of treating CPS. In certain aspects, the invention is drawn to the novel discovery of the role of the zona incerta (ZI) in CPS and methods of exploiting this novel discovery for the treatment of CPS. | 08-12-2010 |
| 20100203047 | Novel Compositions And Methods For Stimulating Erythropoiesis In A Mammal - The present invention relates to compositions comprising an agent which activates herpes virus entry mediator (HVEM). The present invention also relates to compositions comprising an agonist of HVEM. The present invention also relates to methods of stimulating erythropoiesis in a mammal, comprising administering to a mammal a composition comprising an agent which activates HVEM, or is an agonist of HVEM. The present invention also relates to methods for treating an anemic disorder, comprising administering to a mammal suffering therefrom an agent which activates HVEM. | 08-12-2010 |
| 20100184812 | MUTUAL PRODRUGS AND METHODS TO TREAT CANCER - Mutual prodrugs comprising retinoids and histone deacetylase inhibitors, methods for production of the mutual prodrugs, and methods of treatment comprising administration of the mutual prodrugs. The retinoids include all-trans retinoic acid, 13-cis retinoic acid, and retinoic acid analogs that have a substitution at C-4. Further, the mutual prodrugs of the present invention can be used as therapeutic agents for the treatment of cancer and dermatological diseases and conditions. Pharmaceutical compositions comprising the mutual prodrugs. | 07-22-2010 |
| 20100183740 | Potent Inhibitory Effect of Zinc in Combination with Sulforaphane on Cancer Cell Growth - This invention relates to compositions comprising zinc and sulforaphane which can be used in the treatment or prevention of cancer. The invention also relates to methods of treating or preventing cancer, including prostate cancer, which comprises the administration of zinc and sulforaphane to a patient in need thereof. | 07-22-2010 |
| 20100183646 | MAGE-A3/HPV 16 PEPTIDE VACCINES FOR HEAD AND NECK CANCER - The present invention relates to Trojan antigens, and immunogenic compositions comprising the Trojan antigens. The present invention also relates to methods of generating an immune response in a subject using the Trojan antigens or immunogenic compositions. The present invention further relates to methods of treating squamous cell carcinoma of the head and neck (SCCHN) using the Trojan antigens and immunogenic compositions of the present invention. | 07-22-2010 |
| 20100173323 | GLYCOSYLATION ENGINEERED ANTIBODY THERAPY - The instant invention is drawn to methods of generating a glycosylation-engineered antibody, and using the glycosylation-engineered antibody for treating a patient, particularly a cancer patient or a patient with an immune disease or disorder. The instant invention is also drawn to methods of generating a glycosylation-engineered antibody for use in the treatment of patients having a polymorphism that does not respond to conventional antibody therapy. The instant invention is also drawn to methods of improving the biological activity of an antibody by glycosylation engineering. The instant invention is also drawn to methods of modulating antibody-dependent cell-mediated cytoxicity (ADCC) using a glycosylation-engineered antibody. | 07-08-2010 |
| 20100173301 | PROGNOSTIC TOOLS TO PREDICT THE EFFICACY OF DRUG TREATMENT TARGETING CHROMATIN DNA OR ENZYMES ACTING ON DNA - Disclosed are methods of predicting cell response to drug-based therapy using both PCR-Stop assays and real time PCR assays. Methods herein may be used for assessment of drug effect, evaluation of regimen suitability for a given patient, and/or for determination of an optimal drug dose. Also provided are isolated oligonucleotide primers such as primers capable of annealing under PCR conditions to a segment of a c-myc locus, where the primers may be used in the disclosed methods. Further disclosed are kits and systems that may be used for predicting a cell response to drug-based therapy. | 07-08-2010 |
| 20100167392 | FACTOR VIII COMPOSITIONS AND METHODS - The present invention provides methods of increasing the half-life and/or specific activity of factor VIII. More specifically, the invention provides methods of increasing the half-life and/or specific activity of factor VIII by substituting one or more amino acids in the A2 domain. It further provides methods for producing such factor VIII mutants. The invention also provides polynucleotides encoding the mutant factor VIII, and methods of treating hemophilia using the polypeptides and polynucleotides of the invention. | 07-01-2010 |
| 20100113600 | ANTI-CANCER AGENTS AND ANDROGEN INHIBITION ACTIVITY COMPOUND - A qualitative 3D pharmacophore model (a common feature based model or Catalyst HipHop algorithm) developed from well-known natural product androgen receptor down-regulating agents (ARDAs). The 3D pharmacophore model is used as a template in virtual screening compounds for new ARDAs. ARDA compounds and compounds that strongly inhibit the growth of human prostate LNCaP cells. The compounds may be used in compositions and methods of inhibiting cell proliferation of a cancer and methods of preventing or treating cancer, including prostate cancer. | 05-06-2010 |
| 20100094119 | METHOD AND EQUIPMENT FOR IMAGE-GUIDED STEREOTACTIC RADIOSURGERY OF BREAST CANCER - A method of treating a cancerous region in a breast of a patient comprising (i) imaging the breast in a three-dimensional coordinate system, (ii) stereotactically determining the location of the cancerous region in the breast, (iii) optionally determining the volume of the entire cancerous region to be treated, and (iv) while maintaining the breast in a three-dimensional coordinate system that is identical to or corresponds with the three-dimensional coordinate system used in (i), noninvasively exposing the cancerous region of the breast of the patient to a cancer-treatment effective dose of radiation; and equipment for use in such a method. | 04-15-2010 |
| 20100093634 | METHODS FOR REGULATING URINARY POTASSIUM - The internalization sequence at the C-terminal end of the ROMK protein has been identified and sequenced. It has been discovered determined that endocytosis is triggered by binding of the ROMK internalization sequence to ARH protein, which is co-localized and expressed with ROMK. New methods of treating or preventing hyperkalemia have been discovered that include administering to a patient who is at risk of developing hyperkalemia or who has hyperkalemia, a therapeutically effective amount of an agent that blocks the interaction of the ROMK internalization sequence with ARH protein, thereby preventing or reducing ARH-induced endocytosis of ROMK. | 04-15-2010 |
| 20100081661 | HEME OXYGENASE INHIBITORS, SCREENING METHODS FOR HEME OXYGENASE INHIBITORS AND METHODS OF USE OF HEME OXYGENASE INHIBITORS FOR ANTIMICROBIAL THERAPY - Inhibitors of microbial heme oxygenase and their use for treatment of microbial infections and bioremediation. The inhibitors of microbial heme oxygenase are useful against a new class of antimicrobial agents to target infections that are persistently difficult to combat with the current spectrum of antimicrobial agents. Screening methods for selecting inhibitors of microbial heme oxygenase. | 04-01-2010 |
| 20100068802 | NOVEL HUMAN ANDROGEN RECEPTOR ALTERNATIVE SPLICE VARIANTS AS BIOMARKERS AND THERAPEUTIC TARGETS - The present invention relates to novel androgen receptor splice variants (AR3, AR4, AR4b, AR5 and AR8) and variants and fragments thereof which have a role in the progression of androgen independent prostate cancer. The invention further relates to compositions and methods which can be used to identify and treat prostate cancer based on these novel androgen receptor splice variants, as well as methods for screening agents which modulate the activity and/or expression of the androgen receptor splice variants. Vectors, host cells and recombinant methods for producing the same and transgenic animals are also provided. | 03-18-2010 |
| 20100021900 | USE OF OMENTIN 1 AND OMENTIN 2 IN THE DIAGNOSIS AND TREATMENT OF DISEASE - The present invention is directed to methods of diagnosing a disease or predicting an increased risk of a disease, such as obesity, obesity-dependent subacute inflammation, atherosclerosis, cardiovascular disease and a metabolic disease, by determining the levels of omentin 1 and 2 protein in a subject, or by determining the levels of omentin 1 and 2 gene expression in a subject. The present invention is also directed to methods of disease treatment using omentin 1 protein and omentin 2 protein. | 01-28-2010 |
| 20090317393 | METHOD OF MODIFYING GLUCOSE ACTIVITY USING POLYPEPTIDES SELECTIVELY EXPRESSED IN FAT TISSUE - Isolated omentin polypeptides that selectively express in omental fat tissue and methods for the use of the polypeptides. The polypeptides can be used in a method for modifying insulin action and/or glucose metabolism in an animal. The polypeptides can be used to promote glucose uptake by animal adipocytes and other cells, tissues, and/or organs. The polypeptides can also used to provide a therapeutic treatment for diseases of or related to glucose metabolism and adipose tissues. The polypeptides are also incorporated into diagnostic tests and testing kits for diagnosing or detecting a disease or condition involving animal tissue that contains, uses, or expresses the polypeptide in an animal suspected of having the disease or condition. | 12-24-2009 |
| 20090311214 | COMPOSITIONS AND METHODS FOR THE INNATE IMMUNE RESPONSE PATHWAY - Autoimmune diseases are the consequence of complex interactions between a mosaic of host genetic factors and etiologic elements. Celiac disease (CD) is an autoimmune disease prevalent in 1% of the general population, but is unique on two accounts; a) the majority (90%) of individuals with CD have the HLA class II DQ2 allele, the others HLA-DQ8 and b) the etiologic agent is gluten proteins from wheat and related prolamins in barley and rye. The disease process is generally considered to be mediated by T cells that recognize HLA-DQ2 specific peptide sequences in gluten. There is currently no therapeutic treatment for CD. To this end, the inventors have identified a novel therapeutic target for CD and innate immune pathways in other inflammatory conditions. | 12-17-2009 |
| 20090161938 | QUANTITATIVE REAL-TIME 4D STRESS TEST ANALYSIS - Stress test analysis is facilitated through the acquired and manipulated use of a sequence of volumetric data regarding the heart (and may particularly comprise the left ventricle) for the assessment of the health state of the heart. Several provided and illustrated examples specifically relate to ultrasound volumetric data, but the volumetric data may be obtained through the use of any imaging modality (e.g., CT, MRI, X-ray, PET, SPECT, etc.) or combination thereof, and may be used to compute one or more functional quantitative metrics (e.g., ejection fraction.) The volumetric data may also be used to render one or more views of the heart, and particularly of the left ventricle. This disclosure relates to these and other uses of such volumetric data, and to some various implementations thereof, such as methods, systems, and graphical user interfaces. | 06-25-2009 |
| 20090143450 | METHOD FOR TREATING CENTRAL PAIN SYNDROM OR FOR INDUCING CENTRALLY GENERATED PAIN IN AN ANIMAL MODEL - The present invention provides a method for treating central pain syndrome in a mammal by administering an effective amount of a thalamic anticonvulsant compound. Also provided are methods for inducing centrally generated pain responses in an animal model and for screening and identifying a compound that inhibits T-type calcium channels. | 06-04-2009 |
| 20090130144 | Direct vaccination of the bone marrow - The present invention provides methods for eliciting an effective immune response against a weakly immunogenic disease or for priming T cells to become memory T cells against a weakly immunogenic disease by directly vaccinating into the bone marrow of the patient an antigen associated with the weakly immunogenic disease. Also included in the present invention is an isolated population of human memory CD8 | 05-21-2009 |
| 20090124570 | Methods and Compositions for Facilitating Tissue Repair and Diagnosing, Preventing, and Treating Fibrosis - Compositions and methods for facilitating tissue repair by enhancing the actions of BIGH3 or at least one of its downstream effector molecules in injured tissue, and for the diagnosis, prophylactic and therapeutic treatment of fibrosis by inhibiting the actions of BIGH3 or at least one of its downstream effector molecules, such as PU.1 transcription factor and MMP14. Other disclosed methods include methods of screening and/or identifying compounds useful for facilitating tissue repair, treating fibrosis, or for altering the accumulation or deposition of collagen, comprising contacting BIGH3 or its downstream effector molecules, such as PU.1 or MMP14, with a substance and subsequently determining the effects of the substance on the activity of BIGH3, PU.1, or MMP14. | 05-14-2009 |
| 20090111120 | METHYLATION OF GENES AS A PREDICTOR OF POLYP FORMATION AND RECURRENCE - The present invention provides methods for identifying or assessing probabilities for developing an abnormal condition in subject and for the recurrence of the abnormal condition in the subject after receiving treatment. The method comprises determining the methylation status of at least one gene in the subject and comparing this methylation status to normal methylation status. Differences between the methylation status of the one or more genes is indicative of the subject developing an abnormal condition or for the recurrence of the abnormal conditions after receiving treatment. | 04-30-2009 |
| 20090104199 | Breast Cancer Resistance Protein (BCRP) And The DNA Which Encodes It - The Breast Cancer Resistance Protein is described, as well as the cDNA encoding said protein. This protein has been found to confer resistance to cancer chemotherapeutic drugs. | 04-23-2009 |
| 20090082279 | PEPTIDE ANTAGONISTS OF ZONULIN AND METHODS FOR USE OF THE SAME - Peptide antagonists of zonulin are disclosed, as well as methods for the use of the same. The peptide antagonists bind to the zonula occludens receptor, yet do not physiologically modulate the opening of mammalian tight junctions. | 03-26-2009 |
| 20090048153 | COMPOSITION FOR TREATING SULFUR MUSTARD TOXICITY AND METHODS OF USING SAME - One embodiment of the present invention provides a composition, comprising, in amounts effective to treat sulfur mustard or half sulfur mustard induced toxicity or skin damage: an agent that inhibits alkylation of —SH and >NH protein groups; an agent that reduces —SS— to SH; a scavenger of reactive oxygen species; a substrate that maintains tissue reduction-oxidation status; an agent that protects against invading inflammatory cells and associated oxidative stress; an antagonist of prostaglandin synthesis; and an agent that induces tissue regeneration. Methods of using the composition are also provided. | 02-19-2009 |
| 20090047703 | ERG-1 Peptides and Polynucleotides and Their Use in the Treatment and Diagnosis of Disease - The present invention relates to peptide and polynucleotide fragments of ERG-1, and in particular, human ERG-1a (HERG-1a) and its isoforms, and their use in the treatment and diagnosis of disease, especially cardiac diseases, such as arrhythmias, and cancer. | 02-19-2009 |
| 20090023706 | Method of Treating Organophosphorous Poisoning - The present invention is directed to various methods for treating organophosphorus poisoning in an animal that is at risk of exposure to an organophosphorus compound or preventing organophosphorus poisoning in an animal that has been exposed to an organophosphorus compound, by administering a therapeutically effective amount of galantamine or a salt thereof, or a biologically active analog, derivative, fragment or variant thereof. | 01-22-2009 |
| 20090010923 | TREATMENT OF CANCER WITH ANTI-MUSCARINIC RECEPTOR AGENTS - The present invention relates to methods of treating proliferative disorders of colon cells. The methods comprise administering to the cells an effective amount of at least one agent to reduce M3 muscarinic receptor-mediated transactivation of at least one epidermal growth factor receptor. | 01-08-2009 |
| 20080286310 | Live Attenuated Bacterial Vaccine to Reduce or Inhibit Carriage and Shedding of Enterohemorrhagic Escherichia Coli in Cattle - The invention provides live, attenuated enterohemorrhagic | 11-20-2008 |
| 20080269136 | METHOD OF USE OF PEPTIDE ANTAGONISTS OF ZONULIN TO PREVENT OR DELAY THE ONSET OF DIABETES - A method for preventing or delaying the onset of autoimmune diseases is disclosed. | 10-30-2008 |
| 20080260760 | Prostate-Specific Antigen-Derived Mhc Class H-Restricted Peptides and Their Use in Vaccines to Treat or Prevent Prostate Cancer - The present invention relates to immunogenic peptides derived from human prostate cancer antigen (PSA-derived peptides) and their use as vaccines to treat or prevent prostate cancer. The invention is also related to dendritic cells from a patient having prostate cancer, which dendritic cells have been exposed to one or more PSA-derived peptides, and their use to treat or prevent prostate cancer in the patient. The invention is also directed to T-cells from a patient which cells are specific for PSA-activated peptide(s), and their uses to treat or prevent prostate cancer. | 10-23-2008 |
| 20080249054 | METHOD OF MEASURING LIPID DROPLETS AND APPLICATIONS OF USING THE SAME - The invention relates to methods of screening agents for the ability to regulate lipid metabolism and using said agents to treat diseases or disorders related to lipid metabolism (e.g., obesity, diabetes [non-insulin and insulin dependent], hypertension, coronary artery disease, hyperlipidemia (e.g., LDL, TAGs), hypolipidemia (e.g., HDL), lipid metabolism disorders, lipid deposition disorders, lipodystrophies). In specific embodiments, the invention relates to using a PAT family protein to screen agents for the ability to regulate lipid metabolism and using the same to treat diseases or disorders related to lipid metabolism. In further embodiments, the invention relates to high throughput screening (HTS) methods that can be used in the drug discovery process for screening agents for the ability to regulate lipid metabolism. | 10-09-2008 |
| 20080233094 | Attenuated Salmonella Enterica Serovar Paratyphi a and Uses Thereof - The present invention is drawn to a live, attenuated | 09-25-2008 |
| 20080219972 | Prostatic Acid Phosphatase (Pap) Materials and Methods of Use Thereof in the Prophylactic and Therapeutic Treatment of Prostate Cancer - A nucleic acid molecule comprising at least one nucleotide sequence encoding SEQ ID NO: 14, 15, 19, 41, or a sequence that is at least about 95% identical thereto; a composition comprising same and a method of administering same to induce an immune response; a polypeptide consisting of SEQ ID NO: 14, 15, 19, 41, or a sequence that is at least about 95% identical thereto; a composition comprising same and a method of administering same to induce an immune response; a composition comprising APC, which have been exposed to the polypeptide, and a method of administering same to treat prostate cancer; a composition comprising T-cells, which are specific for an epitope in a polypeptide consisting of SEQ ID NO: 14, 15, 19, or 41 and a method of administering same to treat prostate cancer; a composition comprising an anti-idiotypic antibody having an internal image of an epitope of a polypeptide consisting of SEQ ID NO: 14, 15, 19, or 41 and a method of administering same to treat prostate cancer; and an immortal B-cell line that produces an anti-idiotypic monoclonal antibody having an internal image of an epitope of a polypeptide consisting of SEQ ID NO: 14, 15, 19, or 41. | 09-11-2008 |
| 20080212737 | Techniques For Compensating Movement of a Treatment Target in a Patient - Techniques for improving treatment delivered to a target site in a patient include delivering a treatment from a treatment delivery device to a target site in a patient supported by a patient support structure. During the delivery of treatment, a state of the patient is measured to produce real-time measurement data. Measuring the state is non-invasive; and the measured state is a correlated surrogate for position of the target site. Compensating movement data is determined based on the real-time measurement data to cause the target site to maintain a particular spatial relationship with the treatment delivery device. Either the treatment delivery device, or the support structure, or both, are moved based on the compensating movement data. When the delivery device alone is moved, the correlation between measured state and target site is based on partial least squares applied to pre-treatment measurements of both. | 09-04-2008 |
| 20080199357 | Integrated centrifugal blood pump-oxygenator, an extracorporeal life support system and a method of de-bubbling and priming an extracorporeal life support system - The invention relates to an integrated centrifugal blood pump-oxygenator ( | 08-21-2008 |
